9月30日 - ** 券商H.C. Wainwright给予Skye Bioscience SKYE.O"买入 "评级，看好Skye减肥药的安全性和持久性。
** SKYE股价盘前上涨3.1%，报4美元
** HCW 设定了 20 美元的目标价，称该生物制药公司的实验性药物尼马单抗是一种安全的 GLP-1 添加剂，能以较低剂量长期使用。
** H.C. Wainwright 表示："很大程度上缓冲了下跌空间，小幅利好数据可能会提振股价，强劲的结果使 nimacimab 成为主要的肥胖症辅助药物"。
** 覆盖该公司股票的七位分析师都给予了 "买入 "或更高的评级；PT 中位数为 14.50 美元--LSEG 数据
** 截至上一交易日收盘，SKYE股价年累计上涨37.1%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.